trientine has been researched along with transforming growth factor beta in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barry, B; Chan, YK; Chen, X; Choong, YS; Cooper, GJ; Crossman, DJ; Glyn-Jones, S; Gong, D; Kennedy, J; Lu, J; Phillips, AR; Reddy, S; Ruggiero, K; Zhang, S | 1 |
| Canini, A; Chirico, M; De Luca, A; Di Marino, D; Gismondi, A; Iorio, E; Perta, N; Pisanu, ME; Roccatani, I; Rossi, L; Vitaliti, A | 1 |
2 other study(ies) available for trientine and transforming growth factor beta
| Article | Year |
|---|---|
A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes.
Topics: Albuminuria; Animals; Chelating Agents; Copper; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Fibrosis; Kidney; Kidney Glomerulus; Rats; Transforming Growth Factor beta; Trientine | 2008 |
AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism.
Topics: Amino Acid Oxidoreductases; Biological Availability; Cell Line, Tumor; Cell Movement; Copper; Epithelial-Mesenchymal Transition; Fibronectins; Humans; Proto-Oncogene Proteins c-akt; Transforming Growth Factor beta; Trientine; Triple Negative Breast Neoplasms | 2023 |